DVT = Deep Vein Thrombosis   
NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   
SmPC = Summary of Product Characteristics

* ELIQUIS (apixaban) is an oral, direct factor Xa inhibitor indicated for prevention of stroke / systemic embolism in adult patients with NVAF, with one or more risk factors (such as prior stroke or transient ischaemic attack, age ≥ 75 years, hypertension, diabetes mellitus, symptomatic heart failure [New York Heart Association Class ≥ II]), treatment of DVT and PE, and prevention of recurrent DVT and PE in adults.¹

† Not all patients who start on ELIQUIS for acute DVT / PE will stay on ELIQUIS; some acute DVT / PE patients who receive treatment do not require treatment for the prevention of recurrent DVT / PE. Other patients may be prescribed ELIQUIS for the prevention of recurrent VTE after initial treatment for acute DVT PE with another anticoagulant.¹ This is a decision for the prescribing clinician together with patient involvement in the decision-making.

Reference:

1. ELIQUIS^® (apixaban) Summary of Product Characteristics.